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INTRODUCTION:
For many decades, medication of an acute disease or a 
chronic illness has been accomplished by delivering drugs 
to the patients via various pharmaceutical dosage forms like 
tablets, capsules, pills, creams, ointments, liquids, aerosols, 
injectables and suppositories as carriers. To achieve and 
then to maintain the concentration of drug administered 
within the therapeutically effective range needed for 
medication, it is often necessary to take this type of drug 
delivery systems several times in a day. This results in a 
fluctuated drug level and consequently undesirable toxicity 
and poor efficiency. To minimize this fluctuation, novel 
drug delivery systems have been developed, which include 
niosomes, liposomes, nanoparticles, microspheres, micro-
emulsions, impalatable pumps and magnetic 
microcapsules.1-2
The concept of targeted drug delivery is designed for 
attempting to concentrate the drug in the tissues of interest 
while reducing the relative concentration of the medication 
in the remaining tissues. As a result, drug is localised on 
the targeted site. Hence, surrounding tissues are not 
affected by the drug. In addition, loss of drug does not 
happen due to localisation of drug, leading to get maximum 
efficacy of the medication. Different carriers have been 
used for targeting of drug, such as immunoglobulin, serum 
proteins, synthetic polymers, liposome, microspheres, 
erythrocytes and niosomes.3
Niosomes are one of the best among these carriers. 
Structurally, niosomes are similar to liposomes and also are 
equiactive in drug delivery potential but high chemical 
stability and economy makes niosomes superior than 
liposomes. Both consist of bilayer, which is made up of 
non-ionic surfactant in the case of niosomes and 
phospholipids in case of liposomes. Niosomes are 
microscopic lamellar structures of size range between 10 to 
1000 nm and consists of biodegradable, non-immunogenic 
and biocompatible surfactsnts4. The niosomes are 
ampiphillic in nature, which allows entrapment of 
hydrophilic drug in the core cavity and hydrophobic drugs 
in the non-polar region present within the bilayer hence 
both hydrophilic and hydrophobic drugs can be 
incorporated into niosomes. The structure of niosomes is 
given below in Fig.No.1.5
Figure 1: Structure of niosomes.
MERITS AND DEMERITS OF NIOSOMES
  Merits of niosomes are following 6, 7, 8:
 Niosomes can be novel drug dosage form for drug 
molecules having a wide range of solubility as their 
infrastructure consists of hydrophilic and hydrophobic 
part
 Vesicles had flexible characteristic properties; by 
altering vesicle’s characteristics like vesicle 
composition, size, lamellarity, tapped volume, surface 
charge and concentration the niosomes of desired 
property can be obtained 
 As vesicle suspension is water based vehicle hence 
provide better patient compliancy than oil based 
dosage forms
 By improving oral bioavailability of poorly absorbed 
drugs, by delaying clearance from the circulation and 
by protecting the drug from biological environment 
they improve the therapeutic performance of the drug 
molecules
 They are osmotically active, stable and also increase 
the stability of entrapped drug. Oral, parenteral as well 
as topical routes can be adopted for their 
administration
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 The biodegradable, biocompatible and non-
immunogenic surfactants are used in preparation of 
niosomes and also handling and storage of surfactants 
requires no special conditions
The niosomes suffer certain demerits, which include 
the following9:
 The aqueous suspensions of niosomes may have 
limited shelf life due to fusion, aggregation, leaking of 
entrapped drugs, and hydrolysis of encapsulated drugs
 The methods of preparation of multilamellar vesicles 
such as extrusion, sonication, are time consuming and 
may require specialized equipments for processing 
FACTORS GOVERNING NIOSOME FORMATION: 
Composition of niosome: Theoretically for the niosome 
formation the presence of a particular class of amphiphile 
and aqueous solvent is needed but in certain cases 
cholesterol is required in the formulation to provide 
rigidity, proper shape and conformation to the niosomes.  
Cholesterol also stabilizes the system by prohibiting the 
formation of aggregates by repulsive steric or electrostatic 
effects. An example of steric stabilisation is the inclusion of 
Solulan C24 (a cholesteryl poly-24-oxyethylene ether) in 
doxorubicin (DOX) sorbitan monostearate (Span 60) 
niosome formulations. An example of electrostatic 
stabilization is the inclusion of dicetyl phosphate in 5(6)-
carboxyfluorescein (CF) loaded Span 60 based niosomes10.
Surfactant and lipid level: To make niosomal dispersions 
the surfactant/lipid level is generally kept 10-30 mM (1-
2.5% w/w). If the surfactant, water ratio is altered during 
the hydration step may affect the microstructure of the 
system and it’s properties. If we increasing the 
surfactant/lipid level the total amount of drug encapsulated 
also increases, but the viscosity level of system also 
increase11.
Nature of the encapsulated drug: 
The nature of encapsulated drug influences the niosomal 
formation, generally the physico chemical properties of 
encapsulated drug influence charge and rigidity of the 
niosome bilayer. The encapsulated drug interacts with 
surfactant head groups and develops the charge that creates 
mutual repulsion between surfactant bilayers and hence 
vesicle size increases and also cause the aggregation of 
vesicles, which is prevented by using electrostatic
stabilizers like dicetyl phosphate in 5(6)-carboxyfluorescein 
(CF)12.
Structure of surfactants:
The geometry of vesicle to be formed from surfactants is 
affected by surfactant’s structure, which can be defined by 
critical packing parameters. Geometry of vesicle to be 
formed can be predicated on the basis of critical packing 
parameters of surfactants .Critical packing parameters can 
be defined using following equation,
                 CPP (Critical Packing Parameters) = V/ lc× a0
     Where v = hydrophobic group volume,
                 lc = the critical hydrophobic group length,
                 a0= the area of hydrophilic head group.
From the critical packing parameter value type of miceller 
structure formed can be ascertained as given below,
             If CPP < ½ formation of spherical micelles,
             If ½ < CPP < 1 formation of bilayer micelles,
             If CPP > 1 formation inverted micelles11,13
Temperature of hydration:
Hydration temperature influences the shape and size of the 
niosome, temperature change of niosomal system affects 
assembly of surfactants into vesicles by which induces 
vesicle shape transformation. Ideally the hydration 
temperature for niosome formation should be above the gel 
to liquid phase transition temperature of system14,15.
COMPOSITION OF NIOSOMES
Cholesterol and Non ionic surfactants are the two major 
components used for the preparation of niosomes. 
Cholesterol provides rigidity and proper shape. The 
surfactants play a major role in the formation of niosomes. 
non-ionic surfactants like spans(span 20,40,60,85,80), 
tweens (tween 20,40,60,80) and brij (brij 
30,35,52,58,72,76) are generally used for the preparation of 
niosomes16. Few other surfactants that are reported to form 
niosomes are as follows17,18:
 Ether linked surfactant





Preparation of small unilamellar vesicles
Sonication:
It is a typical method of production of the vesicles in which 
a 10-ml glass vial drug solution in buffer is added to the 
surfactant/cholesterol mixture. Then the mixture is probe 
sonicated at 60°C for 3 minutes using a sonicator with 
titanium probe to yield niosomes. The resulting vesicles are 
small and unilamellar19.
Micro fluidization:
It is a recent technique based on submerged jet principle. In 
this two fluidized streams interact at ultra high velocities 
and move forward through precisely defined micro channel
within the interaction chamber. The impingement of thin 
liquid sheet along a common front is arranged such that the 
energy supplied to the system remains within the area of 
niosomes formation which results in a greater uniformity, 
smaller size and better reproducibility of niosomes 
formed20.
Preparation of multilamellar vesicles
Hand shaking method (Thin film hydration technique):
Surfactant and the other vesicles forming ingredients like 
cholesterol are blended and mixture is dissolved in a 
volatile organic solvent like diethyl ether, chloroform or 
methanol in a round bottom flask. Using rotary evaporator 
the organic solvent is removed at room temperature (20°C), 
by this a thin layer of solid mixture deposited on the wall of 
the flask. The dried surfactant film can be rehydrated with 
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aqueous phase at 60°C with gentle agitation results in 
formation of multilamellar niosomes19.
Trans-membrane pH gradient (inside acidic) drug 
uptake process
(Remote Loading):
In a round-bottom flask blend of Surfactant and cholesterol 
are dissolved in chloroform and the chloroform is then 
evaporated under reduced pressure to obtain a thin film on 
the wall of the flask. The film is hydrated by vortex mixing 
with 300 mM citric acid (pH 4.0). The multilamellar 
vesicles are frozen and thawed three times and then 
sonicated. Aqueous solution containing 10 mg/ml of drug is 
added to this niosomal suspension and vortexed. With 1M 
disodium phosphate the pH of the sample is raised to 7.0-
7.2 and the mixture is then heated at 60°C for 10 minutes to 
produce the desired multilamellar vesicles21, 22.
Preparation of large Unilamellar Vesicles
Reverse phase evaporation technique (REV):
In this method, cholesterol and surfactant (1:1) is added in 
a mixture of ether and chloroform. An aqueous phase 
containing  drug  is  added  to  this  and  the  resulting  two 
phases are sonicated at 4-5°C. A small amount of 
phosphate buffer saline is then added to the clear gel 
formed above and is further sonicated. Under low pressure 
and at 40°C the organic phase is removed. Phosphate-
buffer saline is added to dilute the resulting viscous 
niosome suspension and heated in a water bath at 60°C for 
10 min to yield niosomes23.
Ether injection method:
A solution of surfactant mixture is prepared first and then 
slowly introduced into warm water maintained at 60°C. 
The surfactant mixture in ether is injected through 14-
gauge needle into an aqueous solution of material. Single 
layered vesicles are formed by the vaporization of ether. 
The vesicles of diameter range from 50 to 1000 nm are 
obtained depending upon the conditions used. The small 
amount of ether is often still present in the vesicle 
suspension and is often difficult to remove that is the major 
disadvantage of this method24.
Miscellaneous
Multiple membrane extrusion method:
A blend of surfactant, cholesterol, and di acetyl phosphate 
is dissolved in chloroform and the solvent is evaporated 
leading to formation of thin film. Using aqueous drug 
solution the film is hydrated and the resultant suspension 
extruded through polycarbonate membranes, which are 
placed in a series for up to eight passages. This is a best 
method for controlling niosome size24.
The “Bubble” Method:
It is one step technique by which liposomes and niosomes 
are prepared without the use of organic solvents. Round 
bottomed flask is used as bubbling unit with its three necks 
positioned in water bath to control the temperature. Water-
cooled reflux and thermometer is positioned in the first and 
second neck and nitrogen supply through the third neck. At 
70°C Cholesterol and surfactant are dispersed together in 
the buffer (pH 7.4) and mixed with high shear homogenizer 
for 15 seconds and immediately afterwards “bubbled” at 
70°C using nitrogen gas10.
Formation of niosomes from proniosomes:
In this method of producing niosomes a water-soluble 
carrier such as sorbitol is coated with surfactant resulting in 
the formulation of dry formulation in which each water-
soluble particle is covered with a thin film of dry 
surfactant. This preparation is termed “Proniosomes”. Then 
proniosome powder is filled in a screw capped vial, and 
mixed with water or saline at 80 °C by vortexing, followed 
by agitation for 2 min results in the formation of niosomal 
suspension25.
Emulsion method:
From an organic solution of surfactant, cholesterol, and 
aqueous solution of drug, oil in water (o/w) emulsion is 
prepared. The organic solvent is then evaporated, leaving 
niosomes dispersed in the aqueous phase26,14.
Lipid injection method:
In this process, either mixture of lipids and surfactant is 
first melted and then injected into a highly agitated heated 
aqueous phase containing dissolved drug, or the drug can 
be dissolved in molten lipid and the mixture will be 
injected into agitated, heated aqueous phase containing 
surfactant. This method does not require expensive organic 
phase22.
Niosome preparation using Micelle:
Niosomes may also be formed by the use of enzymes in a 
mixed micellar solution. A mixed micellar solution of C16 
G2, dicalcium hydrogen phosphate (DCP), 
polyoxyethylene cholesteryl sebacetate di ester (PCSD) 
when incubated with esterases converts to a noisome 
dispersion. PCSD is cleaved by the esterases action to yield 
polyoxyethylene, sebacic acid and cholesterol and then 
cholesterol in combination with C16 G2 and DCP then 
yields C16 G2 niosomes22.
Niosome preparation using polyoxyethylene alkyl ether:
Charactersitics like the size and number of bilayers of 
polyoxyethylene alkyl ethers and cholestrol consisting 
vesicles can be changed in alternative way. Small 
unilamellar vesciles transforms to large multilamellar 
vesicles by temperature rise above 600° C, while 
multilamellar vesicles can be transformed into unilamellar 
ones by vigorous shaking at room temperature. It is the 
characteristics for the polyoxythelene alkyl ether 
surfactants to transfromation from unilamellar to 
multilamellar vesicles at higher temperature since it is 
known that polyethyleneglycol (PEG) and water at higher 
temperature demixes due to a breakdown of hydrogen 
bonding between water and PEG moieties27.
Separation of Unentrapped Drug
Various techniques can be accomplished for the removal of 
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CHARACTERISATION OF NIOSOMES
Size:
Shape of niosomal vesicles is assumed to be spherical, and 
various techniques can be used for determination of their 
mean diameter like laser light scattering method, electron 
microscopy, molecular sieve chromatography, 
ultracentrifugation, photon correlation microscopy and 
optical microscopy and freeze fracture electron 
microscopy13,28,29,.
Bilayer formation, Membrane rigidity and Number of 
lamellae:
Bilayer vesicle formation by assembly of non-ionic 
surfactants is characterized by X-cross formation under 
light polarization microscopy and membrane rigidity can be 
measured by means of mobility of fluorescence probe as 
function of temperature. NMR spectroscopy, small angle 
X-ray scattering and electron microscopy are used to 
determine the no of lamellae30,31.
Entrapment efficiency: As described above after 
preparing niosomal dispersion, unentrapped drug is 
separated by dialysis, centrifugation or gel filtration and/ or 
complete vesicle disruption using 50% n-propanol or 0.1% 
Triton X-100 is done for the estimation of the drug 
remained entrapped in niosomes and then  analyzing the 
resultant solution by appropriate assay method for the drug. 
Where, Entrapment efficiency (EF) can be defined by11:
                           Entrapment efficiency (EF) = (Amount 
entrapped/ total amount) x100.
In vitro Release Study
Dialysis:
With the help of dialysis tubing in vitro release rate study 
can be done. A dialysis sac was washed and soaked in 
distilled water. The suspension of vesicle was pipetted into 
a bag made up of the tubing and then sealed and placed in 
200 ml buffer solution in a 250 ml beaker with constant 
shaking at 25°C or 37°C. The buffer was analysed at 
various time intervals, for the drug content by an 
appropriate assay method 32.
Reverse dialysis:
In this technique, niosomes are placed in a number of small 
dialysis tubes containing 1 mL of dissolution medium and 
the niosomes are then displaced from the dissolution 
medium35.
Franz diffusion cell:
In a Franz diffusion cell, the cellophane membrane is used 
as the dialysis membrane. The niosomes are dialyzed 
through a cellophane membrane against suitable dissolution 
medium at room temperature. The samples are withdrawn 
at suitable time intervals and analyzed for drug content37.
In vivo Release Study
For in vivo study niosomal suspension was injected 
intravenously (through tail vein) to the albino rats using 
appropriate disposal syringe. These rats were subdivided 
into groups35.
FACTORS AFFECTING VESICLES SIZE, 
ENTRAPMENT EFFICIENCY, AND RELEASE 
CHARACTERISTICS:
Drug:
Vesicle size increases by entrapment  of  drug  in  
niosomes, probably  by increasing  the  charge  and  mutual  
repulsion  of the surfactant bilayers or  interaction  of  
solute  with  surfactant  head groups. But some drug is 
entrapped in the long PEG chains In case of 
polyoxyethylene glycol (PEG)-coated vesicles, thus 
tendency to increase the size reduces. The degree of 
entrapment is affected by hydrophilic lipophilic balance of 
the drug23.
Amount and type of surfactant:
With increase  in  the  hydrophilic-lipophilic  balance  
(HLB)  of surfactants such as Span 85 (HLB 1.8) to Span 
20 (HLB 8.6) the mean size of niosomes increases 
proportionally, because with an increase in  hydrophobicity  
of  surfactants the surface free energy decreases.
Depending on the temperature, the type of lipid or 
surfactant and the presence of other components such as 
cholesterol the bilayers of the vesicles are either in the so 
called liquid state or in gel state. When the structure of the 
bilayers is disordered it will be in liquid state and if alkyl 
chains are present in a well ordered structure it will be in 
the gel state.
Entrapment efficiency is also affected by phase transition 
temperature of surfactants, for example Span 60 having 
higher phase transition temperature provides better 
entrapment20.
Cholesterol content and charge:
Cholesterol increases the chain order of liquid state bilayers 
and also it decreases the chain order of gel state bilayers. 
The gel state is transformed to a liquid-ordered phase at a 
high cholesterol concentration. An increase in cholesterol 
content of the bilayers resulted in a decrease in the release 
rate of encapsulated material, and therefore an increase in 
the rigidity of the resulting bilayers. The interlamellar 
distance between successive bilayers in multilamellar 
vesicle tends to increase due to presence of charge and 
leads to greater overall entrapped volume34.
Methods of Preparation:
Ether injection method (50-1,000 nm) forms vesicles with 
small diameter than vesicles formed by Hand shaking 
method (0.35-13 nm). By Reverse Phase Evaporation 
(REV) method small-sized niosomes can be produced 
while by microfluidisation greater uniformity and small-
sized vesicles are obtained20.
Resistance to osmotic stress:
If in a suspension of niosomes hypertonic salt solution is 
added, reduction in diameter occurs. In hypotonic salt 
solution, probably due to inhibition of eluting fluid from 
vesicles, there is initial slow release with slight swelling of 
vesicles, followed by faster release, which may be due to 
mechanical loosening of vesicles structure under osmotic 
stress35.
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Applications
Niosomal drug delivery is potentially applicable to many 
pharmacological agents for their action against various 
diseases. Few of their therapeutic applications are as 
follows:
Targeting of bioactive agents
1. To reticulo-endothelial system (RES)
The vesicles occupy preferentially to the cells of RES. It is 
due to circulating serum factors known as opsonins, which 
mark them for clearance. Such localized drug accumulation 
has, however, been exploited in treatment of animal tumors 
known to metastasize to the liver and spleen and in 
parasitic infestation of liver35.
2. To organs other than reticulo-endothelial system 
(RES) 
By use of antibodies, carrier system can be directed to 
specific sites in the body. Immunoglobulins seem to have 
affection to the lipid surface, thus providing a convenient 
means for targeting of drug carrier. Many cells have the 
intrinsic ability to recognize and bind particular 
carbohydrate determinants and this property can be used to 
direct carriers system to particular cells36, 37.
Neoplasia
The anthracyclic antibiotic Doxorubicin, with broad 
spectrum anti tumour activity, shows a dose dependant 
irreversible cardio toxic effect. The half-life of the drug 
increased by its niosomal entrapment of the drug and also 
prolonged its circulation and its metabolism altered. If the 
mice bearing S-180 tumour is treated with niosomal 
delivery of this drug it was observed that their life span 
increased and the rate of proliferation of sarcoma 
decreased38. 
Methotrexate entrapped in niosomes if administered 
intravenously to S-180 tumour bearing mice results in total 
regression of tumour and also higher plasma level and 
slower elimination39, 40.
Delivery of peptide drugs
Niosomal entrapped oral delivery of 9-desglycinamide, 8-
arginine vasopressin was examined in an in-vitro intestinal 
loop model and reported that stability of peptide increased 
significantly41. Immunological applications of niosomes
For studying the nature of the immune response provoked 
by antigens niosomes have been used. Niosomes have been 
reported as potent adjuvant in terms of immunological 
selectivity, low toxicity and stability42.
Niosome as a carrier for Hemoglobin
Niosomal suspension shows a visible spectrum 
superimposable onto that of free hemoglobin so can be 
used as a carrier for hemoglobin. Vesicles are also 
permeable to oxygen and hemoglobin dissociation curve 
can be modified similarly to non-encapsulated 
hemoglobin43.
Transdermal delivery of drugs by niosomes
An increase in the penetration rate has been achieved by 
transdermal delivery of drug incorporated in niosomes as 
slow penetration of drug through skin is the major 
drawback of transdermal route of delivery for other dosage 
forms. The topical delivery of erythromycin from various 
formulations including niosomes has studied on hairless 
mouse and from the studies, and confocal microscopy, it 
was found that non-ionic vesicles could be formulated to 
target pilosebaceous glands24.
Diagnostic imaging with niosomes
Niosomal system can be used as diagnostic agents. 
Conjugated niosomal formulation of gadobenate 
dimeglcemine with [N-palmitoylglucosamine(NPG)],PEG 
4400, and both PEG and NPG exhibit significantly 
improved tumor targeting of an encapsulated paramagnetic 
agent assessed with MR imaging44.
Leishmaniasis therapy 
Derivatives of antimony are most commonly prescribed 
drugs for the treatment of leishmaniasis. These drugs in 
higher concentrations – can cause liver, cardiac and kidney 
damage. Use of niosomes as a drug carrier showed that it is 
possible to overcome the side effects at higher 
concentration also and thus showed greater efficacy in 
treatment34.
Niosome formulation as a brain targeted delivery 
system for the vasoactive intestinal peptide (VIP)
Radiolabelled (I125) VIP-loaded glucose-bearing niosomes 
were injected intravenously to mice. Encapsulated VIP 
within glucose-bearing niosomes exhibits higher VIP brain 
uptake as compared to control45.
Ophthalmic drug delivery
From ocular dosage form like ophthalmic solution, 
suspension and ointment it is difficult to achieve excellent 
bioavailability of drug due to the tear production, 
impermeability of corneal epithelium, non-productive 
absorption and transient residence time. But niosomal and 
liposomal delivery systems can be used to achieve good 
bioavailability of drug. Bioadhesive-coated niosomal 
formulation of acetazolamide prepared from span 60, 
cholesterol stearylamine or dicetyl phosphate exhibits more 
tendencies for reduction of intraocular pressure as 
compared to marketed formulation (Dorzolamide) 46.
Other Applications
a) Sustained Release
Drugs with low therapeutic index and low water solubility 
could be maintained in the circulation
via niosomal encapsulation, through niosomes sustained 
release action can be obtained. Azmin et al 30 suggested the 
role of liver as a depot for methotrexate after niosomes are 
taken up by the liver cells.
b) Localized Drug Action
To achieve localized drug action, niosomal dosage form is 
one of the approaches because of the size of niosomes and 
their low penetrability through epithelium and connective 
tissue the drug localized at the site of administration. This 
results in enhancement of efficacy and potency of the drug 
and also reduces its systemic toxic effects e.g. Antimonials 
encapsulated within niosomes are taken up by mononuclear 
cells resulting in localization of drug, increase in potency 
and hence decrease both in dose and toxicity10,34.
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Table 1: List of Drugs formulated as Niosomes
Routes of drug administration                                     Examples of Drugs
Intravenous route                                           Doxorubicin, Methotrexate, Sodium Stibogluconate, Iopromide, Vincristine, Diclofenac 
Sodium, Flurbiprofen, Centchroman,  Indomethacin, Colchicine,Rifampicin, Tretinoin, 
Transferrin and Glucose ligands, Zidovudine, Insulin,Cisplatin, Amarogentin, 
Daunorubicin, Amphotericin B, 5-Fluorouracil, Camptothecin, Adriamycin, Cytarabine 
Hydrochloride
Peroral route                                              DNA vaccines, Proteins, Peptides, Ergot, Alkaloids, Ciprofloxacin, Norfloxacin, Insulin
Transdermal route                                     Flurbiprofen, Piroxicam, Estradiol                                                                                    
Levonorgestrol,Nimesulide,Dithranol, Ketoconazole, Enoxacin, Ketorolac
Ocular route                                            Timolol Maleate, Cyclopentolate
Nasal route                                       Sumatriptan, Influenza Viral Vaccine
Inhalation                                                All-trans retinoic acids
CONCLUSION:
Neosomal drug delivery system is one of the examples of 
great evolution in drug delivery technologies. The concept 
of drug incorporation in the niosomes and to target the 
niosomes to the specific site is widely accepted by 
researchers and academicians. They represent alternative 
vesicular systems with respect to liposomes also having 
various advantages over liposomes like cost, stability etc. 
Niosomes represent a promising drug delivery technology 
and much research has to be inspired in this to juice out all 
the potential in this novel drug delivery system.
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